Phaseline

Companies › ThromBio

ThromBio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TBO-309
PI3Kβ inhibitor that blocks platelet activation, adhesion, and aggregation
PIK3CBPhase 2Ischemic Stroke; Acute Ischemic StrokeDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05363397TBO-309Phase 2Acute Ischemic StrokeNeurologyFeb 2026
NCT06813651TBO-309Phase 2Ischemic StrokeNeurologyDec 2026

Targets

PIK3CB (1)

Companies with the same targets

Restorbio Celcuity Eli Lilly Sovargen

Companies built like this

Dasher Neuroscience Appello Pharmaceuticals PhenoNet Glycomine RyCarma Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.